Introduction
============

The utilization of dose-escalated (DE) radiotherapy for the primary treatment of clinically localized prostate cancer has become increasingly prevalent since the demonstration of improved outcomes with doses above 70 Gy.[@b1-ott-7-1519],[@b2-ott-7-1519] Intensity-modulated radiotherapy (IMRT) with image guidance has been widely accepted as a valuable technique of dose-escalation, with favorable long-term biochemical control and excellent mature toxicity profiles.[@b3-ott-7-1519],[@b4-ott-7-1519] The addition of androgen deprivation therapy (ADT) to conventional radiotherapy doses has also been shown to improve the outcomes of patients with localized prostate cancer.[@b5-ott-7-1519]--[@b8-ott-7-1519] It is not surprising, then, that the RTOG 94-06 dose-escalation trial (a Phase I, II Dose Escalation Study using 3D-CRT for Adenocarcinoma of the Prostate), using 3D conformal radiotherapy and ADT, has demonstrated a trend towards increased biochemical disease-free survival (bDFS).[@b9-ott-7-1519] Presently, there are few reports of long-term outcomes with ADT in combination with DE image-guided (IG)-IMRT. Variable use of ADT in some reports of DE IMRT make it difficult to accurately determine the clinical outcomes of this treatment combination, with increasing utilization requiring long-term mature follow up to determine the efficacy and safety of DE, particularly when combined with ADT.

This study reports on the 5-year clinical outcomes from one of the largest single-institution experiences with the combination of ADT and definitive DE IG-IMRT in patients with localized prostate cancer.

Materials and methods
=====================

Patient selection and staging
-----------------------------

Following institutional ethics approval, the electronic medical records (Mosaiq; Elekta, Stockholm, Sweden) of an integrated cancer center (North Coast Cancer Institute, NSW, Australia) were searched to identify all patients with prostate cancer treated with definitive DE IG-IMRT and ADT, and with a minimum follow up of 12 months. Exclusion criteria included: patients who did not receive ADT, patients who were post-prostatectomy, patients who were node-positive, and patients with histology other than prostate adenocarcinoma. Staging computed tomography (CT) of the abdomen and pelvis, as well as bone scans were performed on all patients with Gleason 8--10, or with PSA \>20 ng/mL. Patients were deemed low-risk if they had T2a disease or less, PSA \<10 ng/mL, and Gleason 6 or less. High-risk patients had at least one of the following characteristics: T3 disease; PSA \>20 ng/mL; or Gleason 8--10. All other patients were classified as being intermediate-risk.

All patients received ADT using leuprolide monotherapy with 3--6 months of neoadjuvant ADT, and high-risk patients received adjuvant ADT for a planned 2--3 years. All patients underwent transrectal ultrasound-guided insertion of gold fiducial markers and magnetic resonance imaging/CT fusion (unless contraindicated). Patients were planned and treated on an institutional bowel and bladder protocol, involving: low residue diet, the use of aperients, and pretreatment oral fluid regimen to achieve a comfortably full bladder and empty rectum. The planning CT scan (2 mm slices) was performed with the patient positioned supine and immobilized with ankle stocks. All clinical target volumes (CTVs) comprised prostate, the proximal 4--8 mm of seminal vesicles (SV), and any extracapsular extension. Patients with high-risk features had the distal SV: included in the CTV to either full dose (if SV magnetic resonance imaging was positive) or to 50 Gy equivalent via simultaneous integrated boost. All planning target volumes (PTVs) comprised CTV plus 5 mm uniform expansion. The total dose ranged from 73.8 Gy to 81 Gy in 1.8 to 2.0 Gy fractions. Image guidance was achieved by means of daily online kV portal images (matched to fiducial markers), with cone-beam CT on days 1--3, and weekly thereafter. Patients without fiducial markers (\<1% of all patients) underwent daily cone-beam CT matching to soft tissue and bone. All patients were treated on Elekta Synergy linear accelerators. Biochemical failure was classified using the Phoenix definition (PSA nadir plus 2 ng/mL), and all patients with biochemical failure were restaged with CT and bone scans, with salvage androgen deprivation initiated when the PSA reached a level between 10 and 20 ng/mL. Metastatic failure was defined as the date of the first radiologically confirmed metastasis. All toxicity and relapse data was collected prospectively and recorded in the Mosaiq electronic medical record, and toxicity was scored using the common toxicity criteria (CTC) version 3 scoring system. The Kaplan-Meier method and Cox-regression multivariate analysis were used to calculate survival outcomes and predictive variables using the SPSS version 20 statistics package (IBM Corporation, Armonk, NY, USA). Variables included in the multivariate analysis included: age (using the median cut point of ≤71 versus \>71 years), Gleason score (≤7 versus 8--10), PSA (using the median cut point of ≤11 ng/mL versus \>11), and T-stage (T3--4 versus T1--2). All *P*-values were two tailed and considered statistically significant at a level \<0.05.

Results
=======

Outcomes
--------

Between January 2005 and March 2011, 782 patients with localized prostate cancer were treated with DE IG-IMRT and ADT, with a median follow up of 46 months. The characteristics of patients are summarized in [Table 1](#t1-ott-7-1519){ref-type="table"}. Median age was 71 years (range 48--85), median PSA was 11 ng/mL (range 0.6--180), and Gleason scores were 6.6% for Gleason 5--6, 56.3% for Gleason 7, and 37.1% for Gleason 8--10. The median IMRT dose delivered was 78 Gy (range 73.8--81).

Overall, 34 of 782 (4.3%) patients suffered a biochemical relapse. Distant metastases developed in 16 (2.0%) patients, with five (0.6%) patients dying as a result of metastatic prostate cancer. At 5 years, the overall bDFS was 88%, metastasis-free survival was 95%, and prostate cancer-specific survival was 98% ([Figures 1](#f1-ott-7-1519){ref-type="fig"}--[3](#f3-ott-7-1519){ref-type="fig"}, respectively).

Toxicity
--------

Treatment was well tolerated, with late genitourinary (GU) or gastrointestinal (GI) toxicity uncommon. At 5 years, 2.1% of patients experienced grade 2 GU symptoms, with no grade 3 or 4 toxicities reported ([Table 2](#t2-ott-7-1519){ref-type="table"}). Similarly, 5-year GI toxicity was low, with 3.4% of patients developing grade 2 GI toxicity, and no late grade 3 or 4 toxicity reported. Rates of grade 1 and 2 erectile dysfunction were 56.9% and 9.1%, respectively, with no grade 3 erectile dysfunction reported.

Multivariate analysis
---------------------

On Cox multivariate-regression analysis, only the initial PSA (*P*=0.001) and the Gleason score (*P*=0.03) were significant for predicting biochemical failure. A Gleason score \>7 was also found to significantly predict for metastatic failure (*P*=0.01), with no variable significantly predictive of prostate cancer-specific mortality. Additional covariates included in the analysis and found to be nonsignificant were; age (*P*=0.33), T-stage (*P*=0.96), and radiation dose (*P*=0.27).

Discussion
==========

The optimum treatment of clinically localized prostate cancer remains controversial, with three efficacious treatments available: surgery; brachytherapy; and external beam radiotherapy.[@b10-ott-7-1519]--[@b12-ott-7-1519] Most published comparisons do not incorporate modern external-beam radiotherapy techniques utilizing DE IMRT with daily online image-guidance (IG) and few of these series routinely combine radiotherapy with ADT. To our knowledge, the present series is the largest reported series combining DE IG-IMRT and ADT for patients with localized prostate cancer. This single-institution experience showed a high 5-year bDFS of 88%, with very low levels of late toxicity.

It seems likely that both IG and DE contribute to accurate delivery of a tumoricidal dose whilst minimizing toxicity. This technique has been shown by other authors to accurately deliver high-dose radiotherapy to the clinical target volume with sparing of normal tissues.[@b13-ott-7-1519] Randomized studies of DE show clear advantages in terms of bDFS,[@b1-ott-7-1519],[@b2-ott-7-1519] with respectable toxicity profiles when using conformal techniques.[@b14-ott-7-1519] Series omitting daily online IG would be expected to show inferior outcomes compared to the current study, considering the known interfraction target motion.[@b15-ott-7-1519] Despite careful adherence to dose constraints, without image guidance, there will inevitably be variability in dose delivery to the target volume and to the organs at risk.

The relative contributions of DE with robust IG and ADT to the excellent outcomes in this series cannot be quantified, and there is no existing randomized study addressing this question. However, in conventional-dose external-beam radiotherapy, the use of ADT has been shown to produce consistent advantages in terms of bDFS and, in some studies, overall survival outcomes.[@b5-ott-7-1519]--[@b8-ott-7-1519] The mechanism for this advantage is not entirely certain; however, there is some evidence that androgen deprivation impacts favorably on both local (prostate) disease as well as distant micrometastatic disease.[@b16-ott-7-1519] This underlies the rationale for the use of ADT even in the setting of DE IG-IMRT, and due to the potential benefits shown in at least one analysis there have been calls for randomized studies evaluating this.[@b9-ott-7-1519]

The present study is not the only study to demonstrate excellent outcomes when using DE IG-IMRT. Eade et al[@b17-ott-7-1519] demonstrated very high rates of bDFS and low rates of treatment-related toxicity in a series of low-risk patients. In that series, IG-IMRT demonstrated superior bDFS and lower late GI and GU toxicity compared to low dose rate (LDR) brachytherapy. Similarly, Takeda et al[@b18-ott-7-1519] recently published encouraging efficacy and toxicity results of 141 patients treated with DE IG-IMRT at 5-years follow-up. The study by Tomita et al[@b19-ott-7-1519] showed similar results to the present study with regards to low toxicity and encouraging bDFS. They reported on a cohort of 241 patients treated with helical tomotherapy, with a median follow-up of 35 months, with the majority of patients receiving ADT. The rates of late grade 3 GI and GU toxicities were 0.8% and 1.2%, respectively, with a 3-year overall bDFS of 99.4%. The use of DE with ADT, as reported by Zapatero et al,[@b20-ott-7-1519] has previously demonstrated good results, even in the absence of daily online IG and IMRT.

The present study is a retrospective analysis of patients from a single institution and is no substitute for a randomized controlled trial investigating DE IG-IMRT and ADT, however, the widespread implementation of these treatments requires stringent reporting of toxicity and efficacy. The duration of ADT required for the apparent improvement in survival outcomes with radiotherapy is still to be determined, with benefits on tumor control ideally balanced against possible side effects from hormonal therapy; randomized controlled trials to investigate this are needed. In addition, all patients in our study received DE IG-IMRT, with encouraging biochemical control, however, the necessity of DE for all risk groups is unknown, and further investigation into risk factors influencing this treatment decision is required. Longer-term follow-up of our cohort is also necessary as, although we demonstrate excellent 5-year results, it is well known that treatment failure continues to develop with time, and it is possible that toxicity rates could increase in the future. Similar studies with longer-term follow-up are therefore required.

Conclusion
==========

We conclude that there is a high probability of tumor control with DE IG-IMRT combined with ADT, a technique with a low probability of significant late toxicity at 5 years. The long-term disease control and toxicity outcomes of this large cohort treated exclusively in one integrated cancer center corroborate the safety and efficacy of ADT and modern IMRT treating to high doses. Ongoing follow-up is needed to monitor tumor control and rates of late toxicity, as are randomized studies to investigate the optimal duration of ADT and patient selection for DE radiotherapy.
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###### 

Patient demographics

  Demographics                               n (%)
  ------------------------------------------ ------------
  Age, years (median, 71; range 48--85)      
   \<70                                      299 (38.2)
   ≥70                                       483 (61.8)
  PSA, ng/mL (median, 11; range, 0.6--180)   
   \<10                                      359 (45.9)
   10--20                                    299 (38.2)
   \>20                                      124 (15.9)
  Gleason                                    
   \<7                                       52 (6.6)
   7                                         440 (56.3)
   \>7                                       290 (37.1)
  T-stage                                    
   T1/T2                                     630 (80.6)
   T3                                        152 (19.4)

**Abbreviation:** PSA, prostate specific antigen.

###### 

Late (5-year) toxicity outcomes

  CTCAE toxicity (n=144)   Gastrointestinal   Genitourinary   Erectile dysfunction
  ------------------------ ------------------ --------------- ----------------------
  0                        85.4%              70.2%           34.0%
  1                        11.2%              27.7%           56.9%
  2                        3.4%               2.1%            9.1%
  3                        0                  0               0
  4                        0                  0               0

**Abbreviation:** CTCAE, Common Terminology Criteria for Adverse Events.
